Common early complaints can include: Nausea or a mildly unsettled stomach Feeling full after smaller meals Reduced interest in food Bloating or belching Indigestion or heartburn Diarrhea Constipation Abdominal discomfort Fatigue These symptoms overlap with adverse reactions listed in current prescribing information for Wegovy and Zepbound
Industry analysts anticipate a potential regulatory filing as early as late 2026, with approval decisions potentially occurring in 2027 depending on trial outcomes and regulatory review timelines
Alternative GLP-1s are generic versions shipped directly and are priced transparently
Tirzepatide Tirzepatide is a dual agonist, meaning it acts as both a GLP-1 and GIP receptor agonist
Wegovy pen (weekly injection, for weight loss): often starts at 0.25 mg once weekly for 4 weeks, then is gradually increased over time
However, some patients who started these treatments hoping for a new lease on life found themselves facing a different, debilitating battle: severe gastrointestinal complications, including a condition known as gastroparesis, or stomach paralysis. What Are GLP-1 Receptor Agonists
